Magadh Chronicle

Complement 3 Glomerulopathy Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

 Breaking News
  • No posts were found

Complement 3 Glomerulopathy Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

November 16
20:45 2022
Complement 3 Glomerulopathy Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market
DelveInsight Business Research LLP
DelveInsight’s “Complement 3 Glomerulopathy (C3G) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Complement 3 Glomerulopathy (C3G), historical and forecasted epidemiology as well as the Complement 3 Glomerulopathy (C3G) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s Complement 3 Glomerulopathy (C3G) Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Complement 3 Glomerulopathy (C3G), historical and forecasted epidemiology as well as the Complement 3 Glomerulopathy (C3G) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Complement 3 Glomerulopathy (C3G) market report provides current treatment practices, emerging drugs, Complement 3 Glomerulopathy (C3G) market share of the individual therapies, current and forecasted Complement 3 Glomerulopathy (C3G) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Complement 3 Glomerulopathy (C3G) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Complement 3 Glomerulopathy (C3G) market.

 

Some of the key facts of the  Complement 3 Glomerulopathy Market Report:

 

  • In the EU5 countries, the diagnosed prevalence of C3G was found to be maximum in Germany with 820 cases, followed by France with 685 cases in 2017. While, the least number of cases were found in Spain, with 496 cases in 2017.

 

  • In Japan, the diagnosed prevalence of C3G was found to be 912 in 2017.

 

  • A cohort-based study referred by the National Health Service (NHS) England, stated that C3G is a rare disease with an estimated prevalence of 1–2 cases per million in the United Kingdom. In a series of patients from the UK and Ireland with C3G, 21 patients presented with DDD while 59 patients presented with C3GN.

 

Key Benefits of the Complement 3 Glomerulopathy Report:

  • The report covers the descriptive overview of Complement 3 Glomerulopathy (C3G), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

  • Comprehensive insight has been provided into the Complement 3 Glomerulopathy (C3G) epidemiology and treatment in the 7MM

  • Additionally, an all-inclusive account of both the current and emerging therapies for Complement 3 Glomerulopathy (C3G) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

  • A detailed review of the Complement 3 Glomerulopathy (C3G) market; historical and forecasted is included in the report, covering drug outreach in the 7MM

  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Complement 3 Glomerulopathy (C3G) market

Got queries? Click here to learn more about the  Complement 3 Glomerulopathy  Market Landscape

 

 Complement 3 Glomerulopathy Overview

The term Complement 3 glomerulopathy (C3G) was adopted by expert consensus in 2013 to define a group of rare kidneys diseases driven by dysregulation of the complement cascade. It is a type of glomerular disease, characterized by predominant C3 complement component (C3) deposits in the glomeruli in the absence of a significant amount of immunoglobulin and without deposition of C1q and C4.

The term C3G includes dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), which are the two patterns of damage and inflammation in the glomeruli. In other words, the damage and inflammation in the kidney tissue in DDD appear different from that in C3GN when observed under a microscope. People with DDD generally present at a younger age (childhood or adolescence) compared to people with C3GN (adulthood).

Dysregulation of the complement alternative pathway, driven by acquired and/or genetic defects, plays a pathogenetic role in C3G. However, alternative pathway abnormalities are also found in IC-MPGN (immune-complex-MPGN). The most common acquired drivers of C3G are the C3 nephritic factors (C3NeFs), heterogeneous autoantibodies that stabilize the C3 convertase, C3bBb.

C3G is also associated with ocular drusen and acquired partial lipodystrophy. Ocular drusen are deposits of complement factors between the retinal epithelium and the underlying Bruch’s membrane. Drusen resemble the deposits of complement factors in the glomeruli and are a result of the structural and functional similarities between the Bruch’s membrane and the glomerular basement membrane

 

Complement 3 Glomerulopathy Epidemiological Insights:

 

  • As per the National Organization for Rare Disorders (NORD), C3G affects persons of all ages, although the mean age appears to be lower in DDD patients as compared to C3GN patients. The prevalence of C3G is estimated at 2–3 per 1,000,000 people

  • A European study included researchers from the US and was conducted by Smith et al. (2019), who highlighted that data derived from four European studies provide estimates of about 0.2–1.0 cases per 1,000,000 of the population. In terms of the point prevalence, values range from 14 to 140 cases per 1,000,000. One of the studies included 19 patients with a median age of 21 years having biopsy-proven C3G from a referral population of 500,000 patients having a prevalence proportion of 1 in 1,000,000

 

  • Ravindran et al. (2018) described the clinicopathological features, complement abnormalities, triggers, treatment and outcomes of patients with C3G. The outcome of the study was out of 114 patients, wherein 102 (89.5%) had a diagnosis of C3GN and 12 (10.5%) of DDD. This provides a key highlight that C3GN was approximately nine-fold more common than DDD during the same period. In terms of gender-specific data, 63 (55.3%) were males and 51 (44.7%) females, with C3GN patients being older than DDD patients.

 

Complement 3 Glomerulopathy Epidemiological Segmentation 

  • Total  Complement 3 Glomerulopathy diagnostic prevelant cases 

  • Total  Complement 3 Glomerulopathy type-specific cases 

  • Total  Complement 3 Glomerulopathy age-specific cases 

Complement 3 Glomerulopathy Market Outlook 

The Complement 3 Glomerulopathy (C3G) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Complement 3 Glomerulopathy (C3G) market trends by analyzing the impact of current Complement 3 Glomerulopathy (C3G) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of the Complement 3 Glomerulopathy (C3G) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Complement 3 Glomerulopathy (C3G) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Complement 3 Glomerulopathy (C3G) market in 7MM is expected to witness a major change in 2019-2032.

Learn more by requesting for sample @ Complement 3 Glomerulopathy Market Trends

 

Complement 3 Glomerulopathy Key Companies

  • ChemoCentryx

  •  Omeros Corporation

  •  Apellis Pharmaceuticals

  •  Novartis Pharmaceuticals

  •  Amyndas Pharmaceuticals

  •  And many others

Complement 3 Glomerulopathy Therapies

  • Avacopan

  • Narsoplimab (OMS721) 

  • Pegcetacoplan (APL-2)

  • LNP023

  • AMY-101

  • And many others 

 

Table of Contents

 

  1. Key Insights 

  2. Report Introduction 

  3. Executive Summary of  Complement 3 Glomerulopathy   

  4. Disease Background and Overview

  5. Epidemiology and patient population

  6. Complement 3 Glomerulopathy   Emerging Therapies

  7.  Complement 3 Glomerulopathy   Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Appendix

  10.  Complement 3 Glomerulopathy   Report Methodology

  11. DelveInsight Capabilities

  12. Disclaimer

  13.  About DelveInsight

Click here to read more about Complement 3 Glomerulopathy Market Insight

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/